Scholar Rock Charts High-Stakes Path to SMA Launch

Scholar Rock Holding ((SRRK)) has held its Q1 earnings call. Read on for the main highlights of the call.

Scholar Rock’s latest earnings call struck an upbeat tone, as management highlighted a pivotal quarter that advanced its lead SMA therapy apitegromab toward potential approval on both sides of the Atlantic. Executives balanced confidence in regulatory and commercial progress with candid acknowledgment of manufacturing risks, elevated spending and continued dependence on external financing.

FDA Acceptance of BLA Sets Clear Path to 2026 Decision

The U.S. Food and Drug Administration has accepted Scholar Rock’s biologics license application for apitegromab in children and adults with spinal muscular atrophy, assigning a PDUFA action date of Sept. 30, 2026. The filing includes two independent fill‑finish sites, a structure the company believes meaningfully de‑risks the review and creates redundancy ahead of potential launch.

Dual Fill-Finish Strategy Underpins Supply Security

Management emphasized that all drug product required for FDA review has been supplied from a second U.S. fill‑finish facility, which is expected to provide ample commercial inventory in early third quarter 2026, ahead of the PDUFA date. The FDA has also completed an unannounced reinspection of the Catalent Indiana site and now has up to 90 days to classify the facility, leaving multiple potential paths to approval.

European Review On Track for Midyear Milestone

In Europe, the marketing authorization application for apitegromab is advancing, with Scholar Rock guiding to a Committee for Medicinal Products for Human Use opinion around mid‑2026. If timelines hold, the company anticipates a European launch in the second half of 2026, initially focused on Germany as the first major market entry point.

Cash Cushion and Flexible Financing Bolster Launch Plans

Scholar Rock ended the first quarter of 2026 with $480 million in cash, cash equivalents and marketable securities, following a $100 million drawdown on its existing debt facility and $98 million in net proceeds from its at‑the‑market program. The company also retains the option to access a further $150 million upon FDA approval and intends to monetize a priority review voucher, underscoring its reliance on capital markets to fund operations.

Commercial Infrastructure Built for Rapid U.S. Launch

The U.S. commercial organization is being primed for an immediate launch if apitegromab wins approval, with established relationships across roughly 140 SMA treatment centers and some 2,600 prescribing physicians. Scholar Rock has also built a patient services hub, expanded its specialty pharmacy network and secured access to more than 10,000 home‑infusion nurses via partners to support real‑world uptake.

Pipeline Progress Extends Beyond Apitegromab

Beyond its lead asset, Scholar Rock is advancing multiple programs, including ongoing enrollment in the Phase II OPAL study for infants and toddlers under two years old. The company plans to initiate the randomized 60‑patient FORGE Phase II trial in facioscapulohumeral muscular dystrophy midyear, while early‑stage work on subcutaneous apitegromab and high‑potency anti‑myostatin antibody SRK‑439 continues with Phase I data readouts expected later in 2026.

Substantial Unmet Need and Large Addressable SMA Market

Management underscored the clinical need apitegromab aims to address, noting that roughly 95% of SMA patients still experience progressive muscle atrophy despite existing therapies. Based on data indicating about one‑third of U.S. patients have received at least two SMN‑targeted treatments, Scholar Rock estimates a global addressable population of up to 35,000 patients who have received at least one such therapy.

Manufacturing Risk Remains a Key Regulatory Overhang

While the BLA acceptance was a major step, management reminded investors that manufacturing remains the core approvability risk after a prior complete response letter flagged observations at Catalent Indiana as the sole issue. Until the FDA completes its classification of the reinspected facility, a degree of regulatory uncertainty persists, even with the second fill‑finish site now fully integrated into the filing.

European Approval Contingent on U.S. Manufacturing Clearance

The company cautioned that timing for European approval is not entirely independent, as regulators there have linked their assessment to the FDA’s ultimate stance on the Catalent Indiana site. Although dialogue with the European Medicines Agency has been described as constructive, this conditionality means the European launch schedule still hinges partly on U.S. manufacturing outcomes.

No Product Revenue Yet and Heavy Pre-Launch Spending

Scholar Rock remains a pre‑commercial company with no reported product revenue and is currently funding its operations primarily through debt and equity‑like instruments. First‑quarter operating expenses reached $102 million, including $80 million of noncash stock‑based compensation, translating to $84 million on an ex‑SBC basis and highlighting the cost of scaling ahead of a potential global launch.

Label Scope and Payer Dynamics Still Unclear

Even as management voiced confidence in apitegromab’s profile, they stressed that the eventual FDA label, including indication breadth and concomitant use with other SMA therapies, remains uncertain. Payer coverage and policies will also play a critical role in shaping how broadly the drug is used, making it premature to project the ultimate commercial footprint.

FSHD Program Faces Scientific and Competitive Risk

Investors were reminded that the company’s FSHD ambitions carry elevated risk after Roche and Chugai discontinued their anti‑myostatin program in the indication, raising questions about the target. Scholar Rock argues its approach is differentiated, but the high‑profile setback by a competitor underscores that the path to proof‑of‑concept in FSHD is far from guaranteed.

Guidance Emphasizes Regulatory Milestones and Financial Runway

Looking ahead, management reiterated key milestones, including the Sept. 30, 2026 PDUFA date and expected midyear CHMP opinion, with a targeted European launch in the second half starting in Germany. They also reaffirmed their current cash position, recent financing moves, planned priority review voucher monetization, detailed commercial readiness metrics and the timeline for pipeline readouts, signaling confidence in both regulatory progress and balance sheet strength.

Scholar Rock’s earnings call painted a picture of a company approaching a potential inflection point, with apitegromab’s regulatory journey now clearly mapped out but still exposed to manufacturing and market‑access variables. For investors, the story hinges on successful navigation of these risks, disciplined management of high operating costs and execution on a sizeable SMA opportunity that could redefine the company’s trajectory.